16.50Open16.50Pre Close0 Volume0 Open Interest25.00Strike Price0.00Turnover851.67%IV-175.08%PremiumJan 17, 2025Expiry Date21.91Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7134Delta0.0717Gamma0.14Leverage Ratio-0.0648Theta-0.0053Rho-0.10Eff Leverage0.0019Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet